Transcriptomics

Dataset Information

0

Immunomodulatory drugs (IMiDs)- or cereblon E3 ligase modulator (CELMoD)-induced growth suppression of Adult T-Cell Lymphoma/Leukemia (ATL) cells and the intrinsic rolls of cereblon for down-regulation of target proteins and their down-stream effectors


ABSTRACT: Adult T-cell lymphoma/leukemia (ATL) is an aggressive subtype of leukemia/lymphoma caused by human T-cell leukemia virus type-1 (HTLV-1) and existing chemotherapy for ATL remains with extremely poor prognosis. Therefore, more effective therapeutic options are urgent needs for this disease. Since recent two clinical studies proved promising curability of Lenalidomide (LEN, a second-generation immunomodulatory drug [IMiDs]) for ATL patients, we investigated the direct growth-inhibitory machineries of LEN on ATL cells. Among 13 ATL-related cell lines, Hut102 and TL-Om1 exhibited best response to LEN treatment and LEN-induced functional modulation of E3-ubiquitin ligase cereblon (CRBN) induced degradation of hematopoietic-specific ikaros-family transcription factors IKZF1 and IKZF3 followed by suppression of their down-stream effectors IRF4 and c-Myc (both have been implied to promote ATL cell malignancy). Additionally, Hut102 and TL-Om1 displayed impaired expression of IKZF2 (deletion in HuT102 and altered translational variants in TL-Om1). LEN-induced growth inhibition to these two cell-lines seemed to be attributed to functional deprivation of all IKZF1/2/3. While CRBN-knockdown (KD) in HuT102 imposed LEN-resistance, IKZF2-KD in LEN-resistant ED40515 induced LEN sensitivity. DNA microarray analysis on LEN-treated HuT102 and OATL4 (LEN-resistant) displayed distinct LEN-responding transcriptional profiles; restoration of immune competency and oncogenic growth promotion respectively. Oral administration of LEN to HuT102-xenographted SCID mice demonstrated significant reduction of tumor mass. Finally, a novel form of IMiDs or cereblon modulator (CELMoD), iberdomide (IBE) exerted deeper and wider range of growth suppression to ATL cells including IKZF2 down regulation. Altogether, these findings strongly indicate the therapeutic advantages of IMiDs or CELMoD against ATL.

ORGANISM(S): Homo sapiens

PROVIDER: GSE221056 | GEO | 2024/02/15

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-02-15 | GSE221062 | GEO
2011-09-30 | E-GEOD-31421 | biostudies-arrayexpress
2021-06-16 | GSE155597 | GEO
2011-09-30 | E-GEOD-31451 | biostudies-arrayexpress
2020-04-13 | GSE123660 | GEO
2011-10-01 | GSE31451 | GEO
2011-10-01 | GSE31421 | GEO
2016-06-08 | GSE82235 | GEO
2022-05-15 | GSE195729 | GEO
2020-05-06 | GSE81725 | GEO